Puma Biotechnology (PBYI) Cash from Investing Activities (2017 - 2025)
Puma Biotechnology's Cash from Investing Activities history spans 9 years, with the latest figure at -$27.0 million for Q4 2025.
- For Q4 2025, Cash from Investing Activities fell 1062.8% year-over-year to -$27.0 million; the TTM value through Dec 2025 reached -$36.2 million, down 77.06%, while the annual FY2025 figure was -$36.2 million, 77.06% down from the prior year.
- Cash from Investing Activities reached -$27.0 million in Q4 2025 per PBYI's latest filing, down from $506000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $11.2 million in Q3 2023 to a low of -$27.0 million in Q4 2025.
- Average Cash from Investing Activities over 5 years is -$4.0 million, with a median of -$3.4 million recorded in 2021.
- Peak YoY movement for Cash from Investing Activities: soared 278.93% in 2022, then plummeted 1700.0% in 2025.
- A 5-year view of Cash from Investing Activities shows it stood at $4.6 million in 2021, then plummeted by 356.94% to -$11.9 million in 2022, then skyrocketed by 31.19% to -$8.2 million in 2023, then skyrocketed by 71.6% to -$2.3 million in 2024, then plummeted by 1062.8% to -$27.0 million in 2025.
- Per Business Quant, the three most recent readings for PBYI's Cash from Investing Activities are -$27.0 million (Q4 2025), $506000.0 (Q3 2025), and -$11.2 million (Q2 2025).